Orum Therapeutics, Inc.
Financials
Valuation Metrics
Orum Therapeutics, Inc.'s Market Cap is ₩4470B. At end of 2025 it was ₩2.6T. Ranked #524 of 2,419 in KR market (top 22%), #211 of 1,638 on KOSDAQ (top 13%), #57 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 447.02B KRW | KR#524/2,419 Sec#57/231 |
| Revenue | 40.6M KRW | KR#2,393/2,419 Sec#225/231 |
| Net Income | 18.51B KRW | KR#731/2,419 Sec#48/231 |
| Total Assets | 169.32B KRW | KR#1,424/2,419 Sec#108/231 |
| Net Assets | 130.89B KRW | KR#1,225/2,419 Sec#92/231 |
| Employees | 21 | KR#2,246/2,419 Sec#212/231 |
| Value | ||
| P/E | 24.15x | KR#1,232/2,419 Sec#73/231 |
| P/B | 3.42x | KR#2,128/2,419 Sec#170/231 |
| P/S | 18970.38x | KR#2,411/2,419 Sec#228/231 |
| Profitability | ||
| ROE | 14.14% | KR#362/2,419 Sec#25/231 |
| ROA | 10.93% | KR#229/2,419 Sec#18/231 |
| Op. Margin | -161817.85% | KR#2,389/2,419 Sec#224/231 |
| Revenue Growth | -99.89% | KR#2,328/2,419 Sec#212/231 |
| Financial Health | ||
| Debt Ratio | 29.37% | KR#573/2,419 Sec#65/231 |
| Total Debt | 12.40B KRW | KR#1,554/2,419 Sec#137/231 |
| Cash | 4.07B KRW | KR#2,083/2,419 Sec#194/231 |
| Performance | ||
| 1Y Return | -39.29% | KR#1,950/2,419 Sec#176/231 |
| 1M Return | -62.01% | KR#2,380/2,419 Sec#230/231 |
| From 52W High | -85.98% | KR#2,387/2,419 Sec#227/231 |
| 1Y MDD | -85.77% | KR#2,367/2,419 Sec#223/231 |
| Trading | ||
| Volume | 192,822 shares | KR#535/2,419 Sec#66/231 |
| Trading Value | 3.96B KRW | KR#425/2,419 Sec#55/231 |
| Foreign Own. | 7.04% | KR#633/2,419 Sec#55/231 |
| Per Share | ||
| EPS | 851 KRW | KR#786/2,419 Sec#56/231 |
| BPS | 6,017 KRW | KR#1,366/2,419 Sec#96/231 |
Company Info
Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions for both cancer and immune system conditions. The firm specializes in creating degrader-antibody conjugates, an innovative class of drugs that merges traditional antibody-drug conjugate (ADC) technology with targeted protein degradation. Their flagship product candidate, ORM-1153, functions as a GSPT1 protein degrader, specifically engineered to address hematologic malignancies. Orum Therapeutics was established in 2016 and operates out of Daejeon, South Korea.